<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906451</url>
  </required_header>
  <id_info>
    <org_study_id>Simvastatin Post-MI</org_study_id>
    <nct_id>NCT00906451</nct_id>
  </id_info>
  <brief_title>Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction</brief_title>
  <official_title>Phase 4 Study of the Effect of Simvastatin Treatment on Inflammatory Response and Endothelial Function After Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brasilia Heart Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brasilia Heart Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During myocardial infarction, inflammatory response may negatively influence ventricle wall
      remodeling as well as endothelium-dependent vasomotor function in the coronary and systemic
      arterial systems. Statins have been consistently proved to attenuate inflammation and improve
      endothelial function. In this study, we tested the effect of different doses of statin on
      inflammatory response and endothelium-dependent vasodilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During acute coronary syndromes (ACS), the generation of inflammatory mediators negatively
      influences arterial wall remodeling and the endothelium-dependent vasomotor function in the
      coronary and systemic arterial systems. The intensity of this inflammatory upregulation is
      strongly related to the incidence of recurrent coronary events. High dose potent statins can
      rapidly reduce plasma levels of cholesterol-rich lipoproteins and inflammatory activity in
      subjects during ACS. By inference, it is plausible to hypothesize that these effects during
      the acute phase of myocardial infarction may influence the post-discharge endothelial
      dysfunction. So far, data is unavailable to verify this assumption or to define the potency
      required for such statin anti-inflammatory effect in myocardial infarction patients. The
      present study aim to investigate the role of statin dose on the time-course of the
      inflammatory response during the acute phase of myocardial infarction and its late effect on
      endothelium-dependent arterial dilation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elevation of plasma C reactive protein</measure>
    <time_frame>Five days</time_frame>
    <description>Changes in CRP levels between the first and fifth day after myocardial infarction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial Artery Endothelial function</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Inflammation</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>No lipid-lowering</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 20 mg/day for 30 days, till the endothelial function assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin</description>
    <arm_group_label>No lipid-lowering</arm_group_label>
    <arm_group_label>Simvastatin 20 mg</arm_group_label>
    <arm_group_label>Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Less than 24 hours after the onset of MI symptoms

          -  ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two
             contiguous leads

          -  Myocardial necrosis, as evidenced by increased CK-MB and troponin levels

        Exclusion Criteria:

          -  Use of statins for at least 6 months prior the myocardial infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei C Sposito, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brasilia Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Base do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70000000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Sposito AC, Santos SN, de Faria EC, Abdalla DS, da Silva LP, Soares AA, Japiass√∫ AV, Quinaglia e Silva JC, Ramires JA, Coelho OR. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1240-6. doi: 10.1161/ATVBAHA.110.218685. Epub 2011 Mar 3.</citation>
    <PMID>21372302</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Andrei C. Sposito</name_title>
    <organization>University of Brasilia Medical School</organization>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>inflammation</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

